Human PilotPubMed ID: 10449801·1999

Long-Term Safety and Efficacy of Sermorelin in Growth Hormone-Deficient Children: A 5-Year Follow-Up Study

Laron Z, Lilos P, Kauli R.

Hormone Research, 1999 · n = 86

Key finding

Sermorelin maintained normalizing effects on height velocity (mean 6.8 cm/year); no tachyphylaxis or new adverse events over 5 years.

Summary

Extended follow-up of sermorelin-treated GH-deficient children assessing long-term efficacy, compliance, and late adverse events.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SermorelinL4

A growth hormone-releasing hormone analog with a long history of clinical use for GH deficiency diagnosis and therapy.

More research on Sermorelin

Sermorelin Acetate Administration Increases Mean Plasma GH Levels and Reduces Waist Circumference in Obese Men

Journal of Clinical Endocrinology & Metabolism · 2005 · Human RCT

Sermorelin Stimulates Growth Hormone Secretion in Older Adults Independent of Body Mass Index

Metabolism · 2004 · Human Pilot

Sermorelin Acetate in the Treatment of Age-Related Growth Hormone Deficiency: A Randomized Controlled Trial

Aging Clinical and Experimental Research · 2003 · Human RCT

Sermorelin Improves Insulin Secretion and Glucose Tolerance in Older Subjects with Impaired Fasting Glucose

Journal of Clinical Endocrinology & Metabolism · 2002 · Human RCT

Sermorelin Restores Bone Mineral Density in Growth Hormone-Deficient Adults: A 2-Year Randomized Trial

Journal of Clinical Endocrinology & Metabolism · 2002 · Human RCT